Investigational drug · Phase 3
Tersolisib
Also called: LY4064809, STX-478
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Breast Neoplasms, Neoplasm Metastasis, Breast Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
5
Any phase or sponsor naming "Tersolisib"
First trial start
2023
Apr 17, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tersolisib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Breast Neoplasms
- Neoplasm Metastasis
- Breast Cancer
- Solid Tumors, Adult
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Tersolisib" as an intervention, largest first.
Eli Lilly and CompanyEli Lilly (LLY)
NCT05768139 · 880 participants (planned) · Start Apr 17, 2023 · Primary completion Jul 2030
Drug: STX-478; Fulvestrant and 9 more · For: Breast Cancer; Solid Tumors, Adult
Sites: Los Angeles, California; San Francisco, California; Aurora, Colorado · 65 sites in all
- A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07174336 · 800 participants (planned) · Start Dec 22, 2025 · Primary completion May 2029
Drug: LY4064809; Placebo and 7 more · For: Breast Neoplasms; Neoplasm Metastasis
Sites: Anchorage, Alaska; Chandler, Arizona; Phoenix, Arizona · 364 sites in all
- A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast CancerPivotal-lookingNot yet recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07935317 · 120 participants (planned) · Start Dec 2026 · Primary completion Dec 2027
Drug: Abemaciclib; Tersolisib and 3 more · For: Breast Neoplasms
Sites: Los Alamitos, California; Lakewood, Colorado; Atlanta, Georgia · 9 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT07662798 · 60 participants · Start Jul 1, 2026 · Primary completion Sep 3, 2026
Drug: Tersolisib · For: Healthy
Sites: Lenexa, Kansas; San Antonio, Texas
- A Study of Tersolisib (LY4064809) in Participants With Kidney Impairment Compared With Participants With Normal Kidney FunctionNot yet recruiting
Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and CompanyIndustry
NCT07924930 · 32 participants (planned) · Start Nov 2026 · Primary completion Aug 2027
Drug: Tersolisib · For: Renal Insufficiency; Healthy Participant
Sites: Altamonte Springs, Florida; Miami Lakes, Florida
Newest research
PubMed records naming it or its code names, newest first.
- In Silico Identification of Rosmarinic Acid as a Putative Natural Product Binder of the PI3Kα Allosteric Site.
Jia W, Ma Y, Cheng X, et al. · Biology (Basel) 2026
- Targeting PI3Kα with Small Molecules: Progress and Challenges in Tumor Treatment.
Jia W · Curr Issues Mol Biol 2026
- Molecular architecture responsible for specific inhibition of oncogenic PI3Kα mutants by RLY-2608 and STX-478.
Liu X, Chen Y, Li G, et al. · Acta Pharm Sin B 2026
- Benzothiophene-based, orally active PIK3CA H1047R mutant-selective inhibitors for the treatment of HR+/HER2- breast cancer.
Zhao S, Fan X, Jia X, et al. · Eur J Med Chem 2026
- Structural Insights into the Development of Inhibitors Against Cancer-Specific Mutations of PI3Kα.
Liu X, Chen Y, Han W, et al. · Annu Rev Pharmacol Toxicol 2026
- Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kα potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models.
Tyrakis PA, Kampjut D, Steele GF, et al. · Br J Cancer 2025
Also in development for Breast Neoplasms
- AL8326Phase 34 trials
Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- NuvastaticPhase 32 trials
Natureceuticals Sdn Bhd · Fatigue, Colon Cancer, Breast Neoplasms
- HLX11Phase 31 trial
Shanghai Henlius Biotech · Breast Cancer, Breast Neoplasms, HER2-positive Breast Cancer
- Zelenectide pevedotinBT8009Phase 25 trials
BicycleTx Limited · Breast Cancer, Non-Small Cell Lung Cancer, Advanced Solid Tumors
- AL58805Phase 22 trials
Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- endoxifenPhase 22 trials
Atossa Therapeutics, Inc. · Precocious Puberty, Gonadotropin-dependent, Breast Neoplasms, Invasive Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.